



an Open Access Journal by MDPI

## Probing the Role of Alzheimer's Disease Risk Gene Using Human-Induced Pluripotent Stem Cells and Transgenic Animal Models

Guest Editor:

**Dr. Marcos R. Costa**

INSERM U1167, Institut Pasteur  
de Lille, Paris, France

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

Alzheimer's disease (AD) is the leading cause of cognitive impairment and dementia worldwide. Despite the identification of numerous AD risk genes through genome-wide association studies in the last 10 years, a comprehensive understanding of AD pathogenesis remains elusive. Importantly, one out of three AD risk genes is predominantly expressed by a unique cell type of the adult human brain. Therefore, understanding the role of AD risk genes in the pathophysiology of AD requires the use of an appropriate model system allowing the manipulation of gene expression in a cell-type-specific fashion. Therefore, this Special Issue aims to publish original research and review articles focused on the study of AD risk genes using both hiPSC-derived cells and transgenic animal models, with a special emphasis on models harboring genetic modifications in specific cell types.



[mdpi.com/si/148345](https://mdpi.com/si/148345)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)